VAXICAN Information

VAXiCAN™, pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of therapeutic cancer vaccines based on proprietary enveloped virus-like particles (eVLP), which provide the safest and most effective way of instructing and strengthening the Patient's anticancer defense mechanisms. VAXiCAN VLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI). VAXiCAN eVLP vaccines are designed to present the extracellular domains of cancer antigens as well as whole proteins while leveraging the immune system's mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells. First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations. VaxiOmics™ is a fully operational service division of VAXiCAN offering wide-scale fully certified whole genome, viral and protein multiomics, spatial omics, proteomics, sequencing with high-level bioinformatics services in a single location. VaxiOmics™ is Oxford Nanopore and Aviti24 fully certified partner as well as first reference center in Central Europe and supports R&D initiatives (Academia, research institutes), CRO (incl. clinical trials monitoring), CDMO (incl. GMP analytics) and medical diagnostics laboratories as a key EU-based subcontractor.